- Conditions
- Post-operative Pain, Opioid Use, Cleft Palate
- Interventions
- Quadratus lumborum block, Local anesthetic infiltration
- Procedure
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 10,332
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Varicose Veins
- Interventions
- Polidocanol (1%) Microfoam (Varisolve), Endovenous Microfoam Occlusion
- Drug · Procedure
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Durham, North Carolina • Winston-Salem, North Carolina + 4 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 3 more
- Conditions
- Aneurysms, Arteriovenous Malformations
- Interventions
- minocycline, doxycycline
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 13 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
- Interventions
- Standard of care genetic testing group
- Other
- Lead sponsor
- Bionano Genomics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Iowa City, Iowa + 5 more
- Conditions
- Sleep Disturbance in Infancy (Disorder), Neonatal Disease
- Interventions
- Novel Real-time Neonatal Sleep Stage Detection Algorithm
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 1 Day to 1 Year
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hip; Anomaly
- Interventions
- Mobilization with movement and stretching, stretching or control
- Procedure
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Huntington Disease
- Interventions
- Tetrabenazine withdrawal
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
- Interventions
- NHS7108, Zenpep®
- Drug
- Lead sponsor
- Aimmune Nestlé Health Science US R&D, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- QR-421a, Sham-procedure (dose cohort 1&2 only)
- Drug · Other
- Lead sponsor
- ProQR Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
- Conditions
- Leukemia
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,034 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 46
- States / cities
- San Diego, California • Lewes, Delaware • Newark, Delaware + 32 more
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Spartalizumab, Investigator choice of chemotherapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Marietta, Georgia • Detroit, Michigan • New York, New York + 1 more
- Conditions
- Obesity, Myelomeningocele, Pregnancy, Diabetes Mellitus in Pregnancy, Fetal Anomaly
- Interventions
- Open Fetal Repair of Myelomeningocele
- Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Friedreich's Ataxia
- Interventions
- EPI-743
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 12
- States / cities
- Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Sickle Cell Disease
- Interventions
- I-STRONG, Enhanced Usual Care (EUC)
- Behavioral · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Atlanta, Georgia • Cincinnati, Ohio
- Conditions
- Plagiocephaly, Nonsynostotic
- Interventions
- Helmet, home therapies
- Device · Behavioral
- Lead sponsor
- Pat Ricalde,DDS, MD, FACS
- Other
- Eligibility
- 4 Months to 7 Months
- Enrollment
- 226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Tourette Syndrome, Chronic Tic Disorder
- Interventions
- Active Oral Orthotic Treatment, Placebo Oral Orthotic Treatment
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 7 Years to 25 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- Observational
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 31 more
- Conditions
- Genetic Disorder
- Interventions
- Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Genetic Counseling, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Hemophilic Arthropathy
- Interventions
- TRM-201 (Rofecoxib), Placebo
- Drug
- Lead sponsor
- Tremeau Pharmceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 15 more
- Conditions
- Wilson's Disease
- Interventions
- VTX-801
- Genetic
- Lead sponsor
- Vivet Therapeutics SAS
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • New Haven, Connecticut • Orlando, Florida + 3 more
- Conditions
- Transfusional Iron Overload, Beta-thalassemia
- Interventions
- SPD602 (FBS0701, SSP-004184)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Oakland, California • Boston, Massachusetts
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota